Literature DB >> 18575842

Antithrombin level and circuit thrombosis during hemofiltration after cardiopulmonary bypass.

H Lanquetot1, T Leprince, S Ragot, C Boinot, C Jayle, R Robert, L Macchi.   

Abstract

OBJECTIVE: Hemofilter thrombosis occurs frequently during continuous veno-venous hemofiltration in intensive care units. Among coagulation disorders, antithrombin deficiency has been shown to be linked to hemofilter thrombosis. We investigated whether there was an association between antithrombin level activity and hemofilter thrombosis occurrence during early continuous hemofiltration following cardiopulmonary bypass.
DESIGN: Prospective observational study.
SETTING: Intensive care unit in University Teaching Hospital. PATIENTS AND PARTICIPANTS: Forty-eight consecutive patients. MEASUREMENTS AND
RESULTS: Antithrombin level activity was measured just before the start of hemofiltration, and repeated at 24 h intervals for a total of 3 days. Hemofilter thrombosis episodes were recorded at each 24-h interval following antithrombin level activity measurement. Subjects were classified as HT when one or more episodes of hemofilter thrombosis appeared in this period and NHT if none. Morbidity parameters and mortality were recorded. Mean initial antithrombin level activity was low and not different in HT and NHT groups at day 0 (60.6 +/- 20.9% vs. 63.4 +/- 19.9%, P = 0.68). Antithrombin level activity was lower at day 1 (47.2 +/- 12.0% vs. 58.2 +/- 15.2%, P = 0.03) and day 2 (41.2 +/- 15.3% vs. 53.5 +/- 14.1%, P = 0.04) in HT group. However, antithrombin level activity was not shown to be predictive of HT in multivariate analysis. Morbidity and mortality did not differ significantly between the two groups.
CONCLUSION: Only a weak association was found between antithrombin level activity and HT during early veno-venous hemofiltration post-cardiopulmonary bypass. This result was not confirmed in multivariate analysis. DESCRIPTOR: Renal failure: dialysis and hemofiltration.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575842     DOI: 10.1007/s00134-008-1181-x

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  25 in total

1.  Possible strategies to prolong circuit life during hemofiltration: three controlled studies.

Authors:  Ian Baldwin; Han Khim Tan; Nicholas Bridge; Rinaldo Bellomo
Journal:  Ren Fail       Date:  2002-11       Impact factor: 2.606

2.  The disturbance of hemostasis in septic shock: role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution.

Authors:  R Seitz; M Wolf; R Egbring; K Havemann
Journal:  Eur J Haematol       Date:  1989-07       Impact factor: 2.997

3.  Confidence interval estimates of an index of quality performance based on logistic regression models.

Authors:  D W Hosmer; S Lemeshow
Journal:  Stat Med       Date:  1995-10-15       Impact factor: 2.373

4.  Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.

Authors:  Demetrios J Kutsogiannis; R T Noel Gibney; Daniel Stollery; Jun Gao
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

5.  Transfusion requirements during continuous veno-venous haemofiltration: -the importance of filter life.

Authors:  M W Cutts; A N Thomas; R Kishen
Journal:  Intensive Care Med       Date:  2000-11       Impact factor: 17.440

6.  Acquired antithrombin deficiency following severe traumatic injury: rationale for study of antithrombin supplementation.

Authors:  J T Owings; R Gosselin
Journal:  Semin Thromb Hemost       Date:  1997       Impact factor: 4.180

Review 7.  The first international consensus conference on continuous renal replacement therapy.

Authors:  John A Kellum; Ravindra L Mehta; Derek C Angus; Paul Palevsky; Claudio Ronco
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

8.  Haemostatic changes in systemic inflammatory response syndrome during continuous renal replacement therapy.

Authors:  N García-Fernández; F J Lavilla; E Rocha; A Purroy
Journal:  J Nephrol       Date:  2000 Jul-Aug       Impact factor: 3.902

9.  Postoperative antithrombin levels and outcome in cardiac operations.

Authors:  Marco Ranucci; Alessandro Frigiola; Lorenzo Menicanti; Antonio Ditta; Alessandra Boncilli; Simonetta Brozzi
Journal:  Crit Care Med       Date:  2005-02       Impact factor: 7.598

10.  Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: a case-control study.

Authors:  Damien du Cheyron; Bruno Bouchet; Cédric Bruel; Cédric Daubin; Michel Ramakers; Pierre Charbonneau
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

View more
  4 in total

1.  4Ts scoring with hemofiltration or hemodialysis clotting.

Authors:  Theodore E Warkentin
Journal:  J Clin Monit Comput       Date:  2015-02       Impact factor: 2.502

2.  Early graft thrombosis due to antithrombin III deficiency following CABG.

Authors:  P Kovacevic; L Velicki; N Komazec; B Vujin; V Ivanovic; M Golubovic
Journal:  Herz       Date:  2011-02-18       Impact factor: 1.443

3.  Response patterns of routinely measured inflammatory and coagulatory parameters in sepsis.

Authors:  Mirjam Bachler; Tobias Hell; Lukas Schausberger; Christine Schlömmer; Volker Schäfer; Marlies Liebensteiner; Katharina Schäffler; Bettina Schenk; Dietmar Fries; Petra Innerhofer; Christian Niederwanger
Journal:  PeerJ       Date:  2019-06-21       Impact factor: 2.984

Review 4.  Year in review in Intensive Care Medicine, 2008: I. Brain injury and neurology, renal failure and endocrinology, metabolism and nutrition, sepsis, infections and pneumonia.

Authors:  Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Johan Groeneveld; Goran Hedenstierna; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Philipp Metnitz; Jerôme Pugin; Jan Wernerman; Haibo Zhang
Journal:  Intensive Care Med       Date:  2008-12-09       Impact factor: 17.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.